NewsKernal
On the business channel, Appili Therapeutics, trading as APLI on…
BRIEF / BUSINESS / JULY 4, 2026

On the business channel, Appili Therapeutics, trading as APLI on…

~30 sec read

On the business channel, Appili Therapeutics, trading as APLI on the TSX and APLIF on OTCPink, faces a significant pipeline disruption. The biopharmaceutical firm announced receipt of a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases, part of the NIH. This decision ends the contract supporting development of their VXV-01 fungal vaccine candidate, potentially impacting future revenue streams and development timelines for the company's infectious disease focus.

  • On the business channel, Appili Therapeutics, trading as APLI on the TSX and APLIF on OTCPink, faces a significant pipeline disruption
  • The biopharmaceutical firm announced receipt of a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases, part…
  • This decision ends the contract supporting development of their VXV-01 fungal vaccine candidate, potentially impacting future revenue streams and development timelines for…
NEWSBUSINESS
Read full story on NewsKernal